Mucinous Adenocarcinoma: Clinical Trials

7 trials for Mucinous Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 unknown, 1 completed, 1 not yet recruiting. 4 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Not yet recruiting 1, Unknown 1
Phase 12Completed 1, Not yet recruiting 1
Not applicable1Unknown 1
Phase 31Active not recruiting 1

Follow Mucinous Adenocarcinoma: new trials by email Literature Review of Mucinous Adenocarcinoma trials Research Report on Mucinous Adenocarcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Samuraciclib + Gemcitabine & Nab-Paclitaxel - Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic
Phase 1 / Phase 2Not yet recruitingUniversity Health Network, Toronto672026-07-012026-06-24
Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors
FAPI PET/CT - Renal Cell Carcinoma, Gastric Cancer
Not applicableUnknownGuangdong Provincial People's Hospital302024-01-112024-01-22
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Nivolumab, Oxaliplatin - Colorectal Adenocarcinoma, Mucinous Adenocarcinoma
Phase 2Active not recruitingUniversity Hospital, Akershus802022-10-052026-01-07
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Bromelain, Acetylcysteine, Interventional radiology insertion of drain - Pseudomyxoma Peritonei, Peritoneal Cancer
Phase 2UnknownMucpharm Pty Ltd622022-05-012022-03-15
Phase I Trial HIPEC With Nal-irinotecan
nanoliposomal irinotecan - Peritoneal Cancer, Pseudomyxoma Peritonei
Phase 1CompletedStony Brook University182019-10-222022-05-06
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)7982017-01-302026-06-17
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)10522007-12-062025-12-30

Narrower conditions

Adenocarcinoma, Mucinous (7)  ·  Pseudomyxoma Peritonei (3)  ·  Carcinoma, Signet Ring Cell (2)  ·  Colorectal Neoplasms (2)  ·  Neoplasms, Cystic, Mucinous, and Serous (2)  ·  Stomach Neoplasms (2)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Adenocarcinoma, Clear Cell (1)  ·  Adrenocortical Carcinoma (1)  ·  Bile Duct Neoplasms (1)  ·  Brenner Tumor (1)  ·  Carcinoma (1)  ·  Carcinoma, Acinar Cell (1)  ·  Carcinoma, Adenoid Cystic (1)  ·  Carcinoma, Basal Cell (1)

Broader conditions

Adenocarcinoma (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Neoplasms, Glandular and Epithelial (7)  ·  Carcinoma (6)  ·  Neoplasms by Site (5)  ·  Neoplasms, Cystic, Mucinous, and Serous (5)  ·  Digestive System Diseases (4)  ·  Digestive System Neoplasms (4)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)

Interventions

Gemcitabine (2)  ·  Nivolumab (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Acetylcysteine (1)  ·  Bevacizumab (1)  ·  Bromelains (1)  ·  CTLA-4 Antigen (1)  ·  Carboplatin (1)  ·  Disulfides (1)  ·  Docetaxel (1)  ·  Fluorouracil (1)  ·  Immunoglobulin G (1)  ·  Ipilimumab (1)  ·  Leucovorin (1)  ·  Magnetic Resonance Spectroscopy (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Guangdong Provincial People's Hospital (1)  ·  Mucpharm Pty Ltd (1)  ·  Stony Brook University (1)  ·  University Health Network, Toronto (1)  ·  University Hospital, Akershus (1)

Countries

United States (3)  ·  Canada (1)  ·  China (1)  ·  Guam (1)  ·  Japan (1)  ·  Norway (1)  ·  South Korea (1)

Top investigators

Alvaro Arjona Sanchez, MD (1)  ·  Armando Sardi, MD (1)  ·  Christian Kersten, MD, PhD (1)  ·  Edward Levine, MD (1)  ·  Georgios Georgakis, MD (1)  ·  Haroon Choudry, MD (1)  ·  Ignace de Hingh, MD (1)  ·  Joseph Kim, MD (1)  ·  Minsig Choi, MD (1)  ·  Robert L Coleman (1)  ·  Sandip P Patel (1)

Results publications

PMID 28438473, PMID 31722153, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36410913, PMID 37185961, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790

NIH funding

2019 (1), U10CA027469 (1), U10CA180868 (1), U10CA180888 (1)